US commercial claims followed 201,229 adults and 1,139 paediatric patients with obesity and no diabetes for a year after starting a GLP-1 drug. Among adults, 30.7% took the drug on most days across the year, whilst 19.6% stopped straight after starting. Among paediatric patients 20.3% kept taking it, and persistence was higher in the Northeast than the South in both cohorts.
Why it is interesting: A large claims estimate of how long people stay on the GLP-1 drugs in routine practice.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Behavioural science
-
Diet, exercise and sleep
What people eat and how much they move: what the measured evidence says each does to mortality, and what has been shown to change either.
1 this week -
Smoking and vaping
How far smoking has fallen and how many deaths it still causes, what vaping is doing to the people who take it up, and what generational bans will show.
None this week Earlier → -
Alcohol and drug use
What is happening to deaths from alcohol, drugs and suicide, whether they move together, and how much of it is behaviour and how much circumstance.
4 this week -
Social connection
Isolation, loneliness and mortality: what the evidence shows, how far the relationship is causal, and what interventions have shown.
1 this week -
Infection and pandemics
Infection and pandemics: the risks, and how well prepared we are
5 this week -
Adherence and persistence
Whether a treatment is actually taken, for how long, and what changes either.
4 this week
